

Katsuhiko Naoki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7006831/publications.pdf>

Version: 2024-02-01

114
papers

14,662
citations

136885

32
h-index

42364

92
g-index

116
all docs

116
docs citations

116
times ranked

16143
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. <i>Science</i> , 2004, 304, 1497-1500.	6.0	9,038
2	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008, 14, 822-827.	15.2	1,015
3	Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2005, 65, 1479-1488.	0.4	530
4	Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. <i>Cancer Research</i> , 2004, 64, 8816-8820.	0.4	472
5	Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4417-4424.	0.8	405
6	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis. <i>Cancer Research</i> , 2005, 65, 5561-5570.	0.4	309
7	Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts. <i>Journal of Clinical Oncology</i> , 2006, 24, 5079-5090.	0.8	263
8	Missense mutations of the BRAF gene in human lung adenocarcinoma. <i>Cancer Research</i> , 2002, 62, 7001-3.	0.4	224
9	Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC. <i>Molecular Cancer Research</i> , 2013, 11, 759-767.	1.5	179
10	Hypercapnic Acidosis Attenuates Endotoxin-Induced Nuclear Factor- κ B Activation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 29, 124-132.	1.4	143
11	<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 38789-38803.	0.8	137
12	Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. <i>Cancer Cell International</i> , 2008, 8, 15.	1.8	129
13	Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2017, 77, 2078-2089.	0.4	126
14	Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. <i>Clinical Cancer Research</i> , 2005, 11, 565-72.	3.2	125
15	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. <i>Molecular Medicine Reports</i> , 2013, 8, 456-462.	1.1	59
16	Mimicking the niche of lung epithelial stem cells and characterization of several effectors of their <i>in vitro</i> behavior. <i>Stem Cell Research</i> , 2015, 15, 109-121.	0.3	59
17	Activation of EGFR Bypass Signaling by TGF β Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 162-171.	1.9	54
18	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 106-114.	1.5	54

#	ARTICLE	IF	CITATIONS
19	Differential Contribution of Various Adhesion Molecules to Leukocyte Kinetics in Pulmonary Microvessels of Hyperoxia-exposed Rat Lungs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 599-609.	2.5	48
20	Roles of ICAM-1 for Abnormal Leukocyte Recruitment in the Microcirculation of Bleomycin-induced Fibrotic Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 1681-1688.	2.5	48
21	The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. <i>International Journal of Clinical Oncology</i> , 2011, 16, 335-344.	1.0	47
22	Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. <i>Clinical Lung Cancer</i> , 2018, 19, e349-e358.	1.1	45
23	Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 90-96.	0.9	44
24	An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1096-1103.	0.5	43
25	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. <i>Lung Cancer</i> , 2019, 127, 146-152.	0.9	42
26	Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 366-372.	0.9	41
27	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10025-10030.	3.3	41
28	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. <i>Oncotarget</i> , 2017, 8, 105479-105491.	0.8	41
29	Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. <i>Lung Cancer</i> , 2017, 109, 45-51.	0.9	39
30	Plasma Platelet-activating Factor Acetylhydrolase Deficiency in Japanese Patients with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 974-979.	2.5	36
31	Response of Intra-acinar Pulmonary Microvessels to Hypoxia, Hypercapnic Acidosis, and Isocapnic Acidosis. <i>Circulation Research</i> , 1998, 82, 722-728.	2.0	34
32	Prognostic significance of G6PD expression and localization in lung adenocarcinoma. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 38-46.	1.1	34
33	Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 34, 1137-1145.	1.2	33
34	Effect of steroid on hyperoxia-induced ICAM-1 expression in pulmonary endothelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 278, L245-L252.	1.3	31
35	Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. <i>Journal of Cancer</i> , 2017, 8, 1774-1785.	1.2	31
36	A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-3.	0.2	28

#	ARTICLE	IF	CITATIONS
37	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 740-750.	1.9	27
38	Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers. <i>Oncologist</i> , 2018, 23, 1218-1229.	1.9	27
39	A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 197-203.	0.9	26
40	FOXD1 expression is associated with poor prognosis in non-small cell lung cancer. <i>Anticancer Research</i> , 2015, 35, 261-8.	0.5	25
41	The Combination of Multiple Receptor Tyrosine Kinase Inhibitor and Mammalian Target of Rapamycin Inhibitor Overcomes Erlotinib Resistance in Lung Cancer Cell Lines through c-Met Inhibition. <i>Molecular Cancer Research</i> , 2010, 8, 1142-1151.	1.5	24
42	Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. <i>Journal of Pathology</i> , 2015, 235, 593-605.	2.1	23
43	Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. <i>Lung Cancer</i> , 2018, 119, 25-35.	0.9	22
44	Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6039-6047.	0.9	22
45	Effects of hypercapnia and hypocapnia on [Ca ²⁺] _i mobilization in human pulmonary artery endothelial cells. <i>Journal of Applied Physiology</i> , 2001, 90, 2094-2100.	1.2	20
46	Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3335-3343.	1.0	20
47	Methylation-induced downregulation of TFPI-2 causes TMRSS 4 overexpression and contributes to oncogenesis in a subset of non-small cell lung carcinoma. <i>Cancer Science</i> , 2015, 106, 34-42.	1.7	18
48	Bronchoscopic Microsampling is a Useful Complementary Diagnostic Tool for Detecting Lung Cancer. <i>Lung Cancer</i> , 2011, 72, 32-38.	0.9	17
49	Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. <i>Cancer Management and Research</i> , 2019, Volume 11, 4883-4892.	0.9	17
50	Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma. <i>Biomedical Research</i> , 2020, 41, 149-159.	0.3	17
51	Bacillus cereus; Necrotizing Pneumonia in a Patient with Nephrotic Syndrome. <i>Internal Medicine</i> , 2013, 52, 101-104.	0.3	15
52	Multiple roles of extracellular fibroblast growth factors in lung cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 423-429.	1.4	15
53	Radiologic features of precancerous areas of the lungs in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2017, Volume 12, 1613-1624.	0.9	15
54	Development of Necrotizing Myopathy Following Interstitial Lung Disease with Anti-signal Recognition Particle Antibody. <i>Internal Medicine</i> , 2018, 57, 2045-2049.	0.3	15

#	ARTICLE	IF	CITATIONS
55	PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 205-210.	1.0	14
56	Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-EGFR-mutant small cell lung cancer harboring an EGFR mutation: A prospective observational study. <i>Thoracic Cancer</i> , 2019, 10, 880-889.	0.8	14
57	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3916-3929.	0.4	13
58	Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line. <i>International Journal of Oncology</i> , 2015, 46, 430-436.	1.4	12
59	Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma. <i>Biomedical Research</i> , 2019, 40, 17-27.	0.3	12
60	Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 885-893.	1.2	12
61	Impaired Hypoxic Vasoconstriction in Intraacinar Microvasculature in Hyperoxia-exposed Rat Lungs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, 602-609.	2.5	11
62	Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status. <i>Thoracic Cancer</i> , 2018, 9, 967-973.	0.8	11
63	Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2017, 14, 3559-3565.	0.8	10
64	Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Oncology</i> , 2018, 95, 109-115.	0.9	10
65	Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001). <i>Molecular and Clinical Oncology</i> , 2017, 6, 409-414.	0.4	9
66	Nitric oxide differentially attenuates microvessel response to hypoxia and hypercapnia in injured lungs. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R181-R189.	0.9	8
67	Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORC 0604. <i>BMC Cancer</i> , 2017, 17, 377.	1.1	8
68	Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 172-177.	0.7	8
69	<i>EGFR</i>-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib. <i>Internal Medicine</i> , 2018, 57, 1007-1010.	0.3	8
70	Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study. <i>Palliative Medicine</i> , 2021, 35, 943-951.	1.3	8
71	Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2018, 9, 1279-1284.	0.8	7
72	Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 1906-1914.	1.2	7

#	ARTICLE	IF	CITATIONS
73	A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 513-519.	1.1	6
74	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 356-361.	0.6	6
75	Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 488-490.	0.4	6
76	Prognostic significance of IMMT expression in surgically resected lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 2142-2151.	0.8	6
77	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. <i>Lung Cancer</i> , 2020, 146, 160-164.	0.9	6
78	TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma. <i>Biomedical Research</i> , 2020, 41, 53-65.	0.3	6
79	Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress. <i>Oncologist</i> , 2021, 26, e2265-e2273.	1.9	6
80	Effects of active vasoconstriction and total flow on perfusion distribution in the rabbit lung. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1997, 273, R1465-R1473.	0.9	5
81	Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 569-575.	0.6	5
82	Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy. <i>Thoracic Cancer</i> , 2021, 12, 1570-1578.	0.8	5
83	A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 717-722.	1.1	4
84	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1593-1601.	1.9	4
85	Hyperoxia and Hypercapnic Acidosis Differentially Alter Nuclear Factor- κ B Activation in Human Pulmonary Artery Endothelial Cells. <i>Advances in Experimental Medicine and Biology</i> , 1999, 471, 265-270.	0.8	4
86	Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status. <i>Oncology</i> , 2018, 94, 207-214.	0.9	3
87	Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 4911-4921.	0.9	3
88	Abstract 4: ABT-263 is effective in a subset of non-small cell lung cancer cell lines. , 2015, , .		3
89	Fatal Fulminant Pneumonia Caused by Methicillin-Sensitive <i>Staphylococcus aureus</i> Negative for Major High-Virulence Factors Following Influenza B Virus Infection. <i>American Journal of Case Reports</i> , 2015, 16, 454-458.	0.3	3
90	A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab. <i>Oncology Letters</i> , 2017, 13, 3285-3290.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer. <i>Internal Medicine</i> , 2018, 57, 2383-2387.	0.3	2
92	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1065-1071.	1.1	1
93	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. <i>Cancer Biomarkers</i> , 2021, 31, 119-126.	0.8	1
94	Clear cell sarcoma originating in the anterior mediastinum. <i>International Cancer Conference Journal</i> , 2013, 2, 211-214.	0.2	0
95	PD2-3-7: The antitumor effect caused by small molecular agents targeting EGFR, VEGFR2 and their downstream kinases in human non small cell lung cancer cells. <i>Journal of Thoracic Oncology</i> , 2007, 2, S446.	0.5	0
96	Abstract 4956: Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. , 2011, , .		0
97	Abstract 4585: Expression of fibroblast growth factor-9 is associated with poor prognosis of resected non-small cell lung cancer patients. , 2012, , .		0
98	Final result of phase II study of irinotecan (CPT-11) plus oral S-1 for previously treated advanced NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18058-e18058.	0.8	0
99	Abstract 5652: Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.. , 2013, , .		0
100	Modulation of Adhesion Molecule Expression in Pulmonary Vascular Endothelium by Oxygen. , 1998, , 479-483.		0
101	Sequential Multistep Mechanisms for Leukocyte Adhesion: Applicable to Lung Microcirculation?. , 1998, , 603-608.		0
102	Biological Impediment to Oxygen Sensing in Injured Pulmonary Microcirculation Exposed to a High-Oxygen Environment. , 1998, , 410-420.		0
103	Abstract 414: Aberrant DNA methylation and expression of mRNA in EGFR-mutant lung cancer cell line with long-term exposure to gefitinib. , 2014, , .		0
104	Abstract 5195: Claudin-1, a novel target of miR-375 in non-small cell lung cancer. , 2014, , .		0
105	A phase II trial of induction Erlotinib followed by chemotherapy with Platinum + Pemetrexed +/- Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19039-e19039.	0.8	0
106	Abstract 1365: Visualizing the effect of BIBF1120 in lung cancer cells by imaging-massspectrometry (MS). , 2015, , .		0
107	Abstract 3006: Hyperoxia may be a treatment option for NSCLC. , 2015, , .		0
108	Abstract 746: Activation of EGFR bypass signaling through TGF β overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
109	Abstract 3916: Oncogenic potential of FGF9 in lung cancer. , 2015, , .		0
110	Abstract 4230: Visualizing the distribution of metabolites and the efficacy of BIBF1120 on metabolic status of lung cancer derived tumors by imaging mass-spectrometry (MS). , 2016, , .		0
111	The efficacy and safety of nivolumab in advanced non-small cell lung cancer in clinical practice in Japan: A multicenter analysis.. Journal of Clinical Oncology, 2017, 35, e20577-e20577.	0.8	0
112	Abstract 2099: In vitro characterization of the effect of nazartinib against non-small cell lung cancer activating clinically relevant EGFR mutants. , 2017, , .		0
113	Abstract 4111: EGFR wild type allele amplification induces acquired resistance to mutation-specific EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. , 2017, , .		0
114	The Clinical Impact of the Post-progression Survival on the Overall Survival in Elderly Patients or Those with a Poor Performance Status and Extensive-disease Small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 10-16.	0.0	0